本文源自：金融界 中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生 产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗 领域具有优势。公司自从2000年上市以来，在MSCI全球标准指数、恒生指数等多个指数中成为成分 股，连续六年入选《制药经理人》的"全球制药企业TOP50"，核心企业正大天晴药业集团、北京泰德制 药股份有限公司多年位列中国医药工业企业百强榜，公司产品收入占比逐年提升。 作者：行情君 截至2025年中报，中国生物制药营业总收入175.75亿元、净利润33.89亿元。 8月21日，中国生物制药(01177)盘中上涨2.01%，截至09:58，报7.61元/股，成交3.03亿元。 8月19日，浦银国际证券维持买入评级,目标价9.1港元。 ...

格隆汇8月21日丨根据联交所最新权益披露资料显示，2025年8月20日，中国生物制药(01177.HK)获执行董事谢炘在场内以每股均价7.368港元增持100万股， 涉资约736.8万港元。 | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日 相關法 | | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | (請參閱上述 *註 | 有投票楼股期(日/月/ 份權益 | | | | | | | 8 | 份百分比 年) | | DA20250820E00018 | 謝沂 1101(L) 1,000,000(L) | | | HKD 7.3680 | 359,557,270(L) | 1.92(L)20/08/2025 | 增持后，谢炘最新持股数目为359,557,270股，持股比例由1.91%上升至1.92%。 | 股份代號: | 01177 | | --- | --- | | 上市法國名稱: | 中國生物製藥有限公司 | | 日期 ...

Group 1 - China National Pharmaceutical Group announced that the selective HER2 tyrosine kinase inhibitor "Zongaitini" has received breakthrough therapy designation from the Center for Drug Evaluation (CDE) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) carrying HER2 tyrosine kinase domain (TKD) activating mutations [1] - The breakthrough therapy designation is based on data from the Beamion LUNG-1 clinical trial, which is a Phase Ia/Ib open-label trial assessing the safety, maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of Zongaitini in patients with HER2-mutant solid tumors [1] - The five-year survival rate for advanced non-small cell lung cancer patients is less than 30%, with approximately 2-4% of NSCLC driven by HER2 gene mutations, indicating a significant unmet medical need for targeted therapies in this patient population [1] Group 2 - Zongaitini is a covalent, orally administered selective HER2 small molecule inhibitor developed by Boehringer Ingelheim, which covalently binds to both wild-type and mutant HER2 receptors while preserving wild-type EGFR signaling, ensuring efficacy along with good tolerability and safety [2] - Zongaitini has previously received priority review and breakthrough therapy designation from CDE for the indication of previously treated patients with advanced HER2-mutant NSCLC, and it received accelerated approval from the U.S. Food and Drug Administration (FDA) in August [2]

Group 1 - China National Medical Products Administration (NMPA) has granted breakthrough therapy designation to the selective HER2 tyrosine kinase inhibitor, Zongaitini, for first-line treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) activating mutations [1] - The breakthrough designation is based on data from the Beamion LUNG-1 clinical trial, which is an open-label Phase Ia/Ib trial assessing the safety, maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of Zongaitini in patients with HER2-mutant solid tumors [1] - The five-year survival rate for advanced NSCLC patients is less than 30%, with approximately 2-4% of NSCLC driven by HER2 gene mutations, indicating a significant unmet medical need for targeted therapies in this patient population [1] Group 2 - Zongaitini, developed by Boehringer Ingelheim, is a covalent, oral selective HER2 small molecule inhibitor that covalently binds to both wild-type and mutant HER2 receptors while preserving wild-type EGFR signaling, ensuring efficacy along with good tolerability and safety [2] - Zongaitini has previously received priority review and breakthrough therapy designation from the NMPA for the indication of previously treated patients with advanced HER2-mutant NSCLC, and it has also received accelerated approval from the U.S. Food and Drug Administration (FDA) [2] - Boehringer Ingelheim has established a strategic partnership with the group to bring innovative oncology therapies to the mainland China market, leveraging both parties' complementary strengths to provide better treatment options for cancer patients [2]

（於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 選擇性HER2 TKI「宗艾替尼」再次獲得CDE突破性治療資格認定 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，選擇性 HER2酪氨酸激酶抑制劑(TKI)「宗艾替尼」再次獲得中國國家藥品監督管理局藥品審評中心(CDE)突破 性治療資格認定，用於治療攜帶HER2酪氨酸激酶結構域(TKD)激活突變的不可切除或轉移性非小細 胞肺癌(NSCLC)成人患者的一線治療。 此次突破性治療資格認定是基於其Beamion LUNG-1臨床試驗數據。這是一項Ia/Ib期首次人體開放 標籤試驗，以確定宗艾替尼在HER2突變實體瘤患者中的安全性、最大耐受劑量(MTD)、藥代動力學 (PK)、藥效學(PD)及初步療效(NCT04886804)。最新數據將於今年晚些時候公布。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責 ...

香港联交所最新资料显示，8月20日，副总裁兼执行董事谢炘增持中国生物制药(01177)100万股，每股 作价7.368港元，总金额为736.8万港元。增持后最新持股数目约为3.6亿股，最新持股比例为1.92%。 ...

香港联交所最新资料显示，8月20日，副总裁兼执行董事谢炘增持中国生物制药(01177)100万股，每股 作价7.368港元，总金额为736.8万港元。增持后最新持股数目约为3.6亿股，最新持股比例为1.92%。 ...

Group 1 - The core viewpoint of the report indicates that China Biopharmaceutical's revenue increased by 10.7% year-on-year in the first half of the year, with net profit rising by 12.3% and adjusted net profit soaring by 101.1%, surpassing expectations due to better-than-expected growth in innovative product revenue and dividend income [1] - The firm anticipates that the approval process for innovative products will accelerate over the next three years, potentially driving additional revenue for the company [1] - Due to improvements in operational efficiency and increased dividend income, the firm has raised its adjusted net profit forecasts for the next two years by 16.9% and 17.2%, to 4.47 billion and 4.921 billion yuan respectively [1] Group 2 - The firm maintains an "outperform" rating for the company and has raised the target price by 17.1% to 8.9 HKD [1]

智通财经APP获悉，中银国际发布研报称，中国生物制药(01177)上半年收入同比增长10.7%，符合预 期，主要来自于创新药、生物类似药销售强劲，以及仿制药销售复苏的推动。持续经营业务净利润同比 大幅增长140%，相信是受到股息收入及金融资产变动的支持。管理层维持2025年双位数增长指引，预 期下半年将录得3亿美元默沙东里程碑付款及潜在BD授权交易。中银国际估算，中生制药的创新药贡献 预计将从2025年的50%上升至2027年的60%，将目标价从7.7港元升至8.7港元，维持"买入"评级。 ...

中银国际发布研报称，中国生物制药(01177)上半年收入同比增长10.7%，符合预期，主要来自于创新 药、生物类似药销售强劲，以及仿制药销售复苏的推动。持续经营业务净利润同比大幅增长140%，相 信是受到股息收入及金融资产变动的支持。管理层维持2025年双位数增长指引，预期下半年将录得3亿 美元默沙东里程碑付款及潜在BD授权交易。中银国际估算，中生制药的创新药贡献预计将从2025年的 50%上升至2027年的60%，将目标价从7.7港元升至8.7港元，维持"买入"评级。 ...